Provalis PLC - Formation of Advisory Board

RNS Number:5511H
Provalis PLC
20 March 2000


          Provalis Appoints Scientific Advisory Board
                                
                                
Provalis plc is pleased to announce the formation of a Scientific
Advisory  Board for its Therapeutics R&D Division.  This Division
is   focused   on  the  development  of  vaccines   and   peptide
therapeutics.

The  Board  will  be chaired by Dr Dudley Earl,  a  non-executive
director of Provalis and formally head of research at Zeneca  plc
(now  AstraZeneca).   The  Board will comprise  Dr  Duncan  Croft
(Therapeutic  Head of Biologics, Beaufour-Ipsen), Professor  Tony
Hart  (Department of Medicine, University of Liverpool), Dr Brian
Morgan  (ex  Technical Licensing, SmithKline Beecham),  Dr  Colin
Pouton (Dept of Pharmacy & Pharmacology, University of Bath)  and
Professor Pamela Riches (St George's Hospital Medical School).

The  Scientific Advisory Board will help guide the  strategy  and
direction  of  the  Company's R&D programmes, will  independently
review  clinical  and pre-clinical data and will  assist  in  the
review of new research targets.

On the formation of the Scientific Advisory Board, Dr Phil Gould,
Chief  Executive Officer of Provalis, said " This is an important
step  for  Provalis.  We have assembled an advisory team  with  a
blend  of  scientific,  developmental and commercial  skills  and
experience which I believe will be a real asset for the Company."

Provalis  is  an  integrated Healthcare company  focused  on  the
development  and global sale of medical diagnostics,  the  supply
and  sale  of  ethical healthcare products in  the  UK,  and  the
development of vaccines to combat infectious diseases.


For further information:-

Dr Phil Gould, Provalis plc:  Tel: 01244 833463
Lisa Baderoon, Buchanan Communications:  Tel: 020 7466 5000


END

MSCEAPDEASLEEEE

Globaldata (LSE:DATA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024